| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025.
"I am very pleased to welcome Matt as our new Chief Financial Officer. Matt's financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Genelux," said Thomas Zindrick, President, CEO and Chairman of the Board. "His unique combination of financial expertise and scientific background will be valuable as the company continues building towards the potential launch of Olvi-Vec."
Mr. Pulisic is an accomplished, senior executive with over 19 years of finance and commercial experience in the biopharmaceutical industry, having worked across the United States, Europe, and Asia. He is recognized for his expertise in financial leadership, corporate strategy and operational execution.
Most recently, Mr. Pulisic served as Vice President of Finance at Arrowhead Pharmaceuticals, a publicly traded RNAi technology company. He played a key role in shaping the company's financial direction, leading planning and analysis, establishing a commercial manufacturing facility, and driving operational improvements to support the company's evolution from a clinical-stage to a pre-commercial organization. He began his career at Amgen, a publicly traded commercial biotechnology company, as a Research Associate and transitioned into finance where he held positions of increasing responsibility, across a breadth of finance-related positions, including Finance Director of Amgen Worldwide and Head of Capital Finance. He graduated from California Lutheran University with his M.B.A. in finance and from the University of California, Santa Cruz with his B.S. in Biochemistry and Molecular Biology.
"I am excited to join the Genelux team and look forward to advancing our financial strategy, delivering enhanced shareholder value and bringing life-changing therapies to patients," said Mr. Pulisic.
In connection with his appointment as Chief Financial Officer, Mr. Pulisic was granted an inducement award of a stock option to purchase 275,000 shares of common stock under the Company's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), at an exercise price of $3.95 per share. The Inducement Option will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and the balance of the underlying option shares vesting monthly thereafter over 36 months, subject to Mr. Pulisic's continued service relationship with the Company through the applicable vesting dates.
Posted In: GNLX
